### (19) World Intellectual Property **Organization**

International Bureau





(43) International Publication Date 31 March 2005 (31.03.2005)

### (10) International Publication Number WO 2005/028511 A3

- (51) International Patent Classification<sup>7</sup>: C07K 16/18, C12N 15/13, 15/79, A61K 39/395, C07K 16/42, G01N 33/68, 33/577, A61P 25/28
- (21) International Application Number:

PCT/US2004/009522

- (22) International Filing Date: 26 March 2004 (26.03.2004)
- (25) Filing Language:
- (26) Publication Language: English
- (30) Priority Data:

60/458,510	28 March 2003 (28.03.2003)	US
60/458,509	28 March 2003 (28.03.2003)	US
60/458,474	28 March 2003 (28.03.2003)	US
60/458,469	28 March 2003 (28.03.2003)	US

- (71) Applicant: CENTOCOR, INC. [US/US]; 200 Great Valley Parkway, Malvern, PA 19355 (US).
- (71) Applicants and
- (72) Inventors: MERCKEN, Marc [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). BENSON, Jacqueline, M. [US/US]; 5 Oak Glen Drive, Malvern, PA 19355 (US).
- (74) Agents: JOHNSON, Philip, S. et al.; One Johnson and Johnson Plaza, New Brunswick, NJ 08933 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### **Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 9 September 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES

(57) Abstract: The present invention relates to at least one anti-amyloid antibody, including isolated nucleic acids that encode at least one anti-amyloid antibody, amyloid, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.



nai Application No PCT7US2004/009522

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K16/18 C12N15/13
G01N33/68 G01N33/577

G01N33/577

C12N15/79 A61P25/28 A61K39/395

C07K16/42

According to International Patent Classification (IPC) or to both national classification and IPC

#### **B. FIELDS SEARCHED**

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-In	ternal, BIOSIS, EMBASE, CHEM ABS	S Data, WPI Data, PAJ, Seque	ence Search
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of	f the relevant passages	Relevant to claim No.
X	WO 02/46237 A (NEURALAB LTD. 13 June 2002 (2002-06-13) examples claims figures 1,2,9,10 sequences 5,8,14,16	& J. WYETH)	2,4,6,8, 20,29-37
X	WO 02/088307 A (ELI LILLY AND 7 November 2002 (2002-11-07) examples claims sequences 4,5	COMPANY)	6,8,20, 29-37
X	EP 1 172 378 A (R. DODEL & Y. 16 January 2002 (2002-01-16) examples claims	DU) -/	18,20, 26,29-31
X Furth	ner documents are listed in the continuation of box C.	X Patent family members are listed in	n annex.
"A" docume consid "E" earlier of filing d "L" docume which in citation "O" docume other n "P" docume	nt which may throw doubts on priority claim(s) or is cited to establish the publication date of another n or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or	<ul> <li>*T* later document published after the inte or priority date and not in conflict with cited to understand the principle or the invention</li> <li>*X* document of particular relevance; the c cannot be considered novel or cannot involve an inventive step when the document of particular relevance; the c cannot be considered to involve an involve and involve and involve and comment is combined with one or moments, such combination being obvious in the art.</li> <li>*&amp;* document member of the same patent</li> </ul>	the application but cory underlying the laimed invention be considered to cument is taken alone laimed invention ventive step when the ore other such docu- us to a person skilled
Date of the a	actual completion of the international search	Date of mailing of the international sear	rch report
28	8 July 2005	03/08/2005	
Name and n	nailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340-3016	Authorized officer	

Internal Application No PCT/US2004/009522

		FC1/032004/009522
C.(Continu	Citation of document, with indication, where appropriate of the relevant passages	Relevant to claim No.
Category *	Citation of document, with indication, where appropriate, of the relevant passages	neievant to ciaim No.
X	Q. FANG ET AL.: "VH and VL gene usage by anti-beta-amyloid autoantibodies in Alzheimer's disease: Detection of highly mutated V regions in both heavy and light chains."  CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 75, no. 2, May 1995 (1995-05), pages 159-167, XP001030584  USA abstract page 160, left-hand column, line 1 - line 22	18
X	J. CAI ET AL.: "Screening and characterization of human single-chain Fv antibody against beta-amyloid peptide 40." NEUROREPORT, vol. 14, no. 2, 10 February 2003 (2003-02-10), pages 265-268, XP008050190 GB the whole document	18,36,37
A	WO 02/088306 A (ELI LILLY AND COMPANY) 7 November 2002 (2002-11-07) examples	1-38
Α	WO 03/016467 A (ELI LILLY AND COMPANY) 27 February 2003 (2003-02-27) examples claims	1-38
Α	F. GASKIN ET AL.: "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease."  JOURNAL OF EXPERIMENTAL MEDICINE, vol. 177, no. 4, April 1993 (1993-04), pages 1181-1186, XP001030627  Tokyo, Japan abstract page 1185, right-hand column, line 24 - line 28	28
Α	F. KAMETANI ET AL.: "A monoclonal antibody Hy20-54-16-3L to lambda light chain of human immunoglobulin reacts with amyloid in Alzheimer's disease brain."  NEUROSCIENCE LETTERS, vol. 117, no. 1/2, 1990, pages 62-67, XP009013620  Limerick, Ireland the whole document	28
	,	

Internation No
PCT/US2004/009522

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J. DAVIES ET AL.: "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding."  IMMUNOTECHNOLOGY, vol. 2, 1996, pages 169-179, XP004070292 abstract	2,6,10, 14
E	WO 2004/029630 A (JANSSEN PHARMACEUTICA N.V.) 8 April 2004 (2004-04-08) sequences 5-12	1-4, 9-16,29, 31,33, 34,36,37
	claims	
Ţ	L. HOLT ET AL.: "Domain antibodies: proteins for therapy." TRENDS IN BIOTECHNOLOGY, vol. 21, no. 11, November 2003 (2003-11), pages 484-490, XP004467495 abstract 'conclusions', first line.	2,6,10,



Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 29-32 (partially, as far as an in vivo method is concerned) are directed to a method of treatment of, and a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest
No protest accompanied the payment of additional search fees.

International Application No
PCT/US2004/009522

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0246237		13-06-2002	AU	2592102 A	18-06-2002
NO ULTULU!	71	13 00 2002	BG	107850 A	27-02-2004
			BR	0115978 A	03-05-2005
			CA	2430772 A1	13-06-2002
			CN	1541225 A	27-10-2004
			CZ	20031601 A3	17-12-2003
			EE	200300264 A	15-10-2003
			ΕP	1358213 A2	05-11-2003
			HU	0302589 A2	28-10-2003
			JP	2005500808 T	13-01-2005
			NO	20032549 A	05-08-2003
			PL	366341 A1	24-01-2005
			SK	8502003 A3	02-03-2004
			WO	0246237 A2	13-06-2002
			US	2003165496 A1	04-09-2003
			US	2005009150 A1	13-01-2005
			ÜS	2004087777 A1	06-05-2004
			US	2004171815 A1	02-09-2004
			US		
				2004171816 A1	02-09-2004
		~	ZA 	200305169 A	09-07-2004 
WO 02088307	Α	07-11-2002	EP	1385544 A2	04-02-2004
			WO	02088307 A2	07-11-2002
			US	2005142131 A1	30-06-2005
EP 1172378	Α	16-01-2002	 ЕР	1172378 A1	16-01-2002
2. 11,20,0	,,	10 01 2002	ŪS	2002009445 A1	24-01-2002
WO 02088306	Α	07-11-2002	EP	1385545 A2	04-02-2004
			WO	02088306 A2	07-11-2002
			US	2005090648 A1	28-04-2005
WO 03016467	Α	27-02-2003	CA	2452104 A1	27-02-2003
NO 03010407			ĔΡ	1429805 A2	23-06-2004
			JΡ	2005500389 T	06-01-2005
			WO	03016467 A2	27-02-2003
			US 	2004241164 A1	02-12-2004
WO 2004029630	Α	08-04-2004	WO	2004029629 A1	08-04-2004
			AU	2003266378 A1	19-04-2004
			CA	2498058 A1	08-04-2004
			WO	2004029630 A1	08-04-2004
			EP	1546734 A1	29-06-2005
				TO TO / OT INT	